EMBC — Embecta Corp. (Stock)

Price: $6.45 · 1 day: +4.37% · 5 days: +12.17% · 1 month: +26.72% · YTD: -45.71%
As of 2026-10-15 20:00 UTC.

52-week range: $2.77 – $14.91 (currently at 30% of the range).

The brief

EMBC is in a turning down, momentum firm. $6.76 is the level overhead; $6 the first support below.

4 of 6 technical checks lean bullish.

• Price vs 50-day: above
• Price vs 200-day: below
• 50d vs 200d avg: below
• MACD: bullish
• RSI momentum: 64
• 5-day tape: +12.2%

Key levels

Indicators

Next earnings: 2026-11-25.

Latest EMBC news

• Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study — Eli Lilly announced detailed results from the Phase 3 ACHIEVE-4 trial evaluating Foundayo (orforglipron) in adults with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The trial met its primar (PR Newswire, 2026-09-30)
• Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes — Eli Lilly announced positive Phase 2b trial results for EloraTZP, an investigational combination of eloralintide and tirzepatide, in 367 adults with obesity or overweight and type 2 diabetes. At 48 weeks, EloraTZP achiev (PR Newswire, 2026-09-30)
• New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis — Eli Lilly announced Phase 3b trial results showing its drug EBGLYSS (lebrikizumab-lbkz) met primary and secondary endpoints in treating moderate-to-severe hand and foot atopic dermatitis. The ADtouch study found that ove (PR Newswire, 2026-09-30)
• Sinocare Showcases Integrated Chronic Disease Management Solutions at EASD 2026 — Sinocare is presenting its integrated chronic disease management portfolio at the EASD 2026 conference in Milan, covering home, pharmacy, and hospital settings. The company unveiled several products, including the Safe A (PR Newswire, 2026-09-30)
• Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes — Eli Lilly announced Phase 3 trial results for retatrutide, a triple hormone receptor agonist, demonstrating substantial clinical efficacy in treating type 2 diabetes and obesity. At 80 weeks, participants receiving the 1 (PR Newswire, 2026-09-29)
• Lilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison — Eli Lilly announced results from an indirect treatment comparison showing that Zepbound (tirzepatide) 10 mg and 15 mg delivered greater weight loss than Wegovy HD (semaglutide 7.2 mg) in adults with obesity. In the analy (PR Newswire, 2026-09-29)
• Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison — Eli Lilly presented new indirect treatment comparison data at the EASD annual meeting showing its oral GLP-1 drug Foundayo (orforglipron) 17.2 mg achieved significantly greater weight loss and A1C reduction than oral sem (PR Newswire, 2026-09-29)
• Lilly launches the Lilly Change the Course Commitment, aiming to address treatment gaps in diabetes and obesity in LMICs — Eli Lilly launched the Lilly Change the Course Commitment, a global health initiative aiming to treat as many people with its diabetes and obesity medicines in low- and middle-income countries (LMICs) as in high-income c (PR Newswire, 2026-09-28)

Explore more

Interactive EMBC chart and analyst chat · Market terminal — movers, signals and news · Use MarketCrew inside Claude · Use MarketCrew inside ChatGPT · Top gainers today · 52-week highs